Anti- igfbp7 antibodies and uses thereof
Humanized antibodies targeting IGFBP7 and its receptors address the limitations of existing therapies by reducing senescence, inflammation, and fibrosis, offering therapeutic benefits in conditions such as psoriasis, heart failure, and acute kidney injury.
Patent Information
- Application Number
- PCT/EP2025/079802
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-10-16
- Filing Date
- 2025-10-15
- Publication Date
- 2026-04-23
AI Technical Summary
Current therapies lack effective anti-IGFBP7 antibodies that bind with high affinity and specificity to human IGFBP7 and/or its receptors, failing to adequately address stress-mediated senescence, inflammation, and pro-fibrotic tissue injury in conditions such as psoriasis, heart failure, and acute kidney injury.
Development of human or humanized antibodies or antigen binding fragments that specifically bind to human IGFBP7 and/or its receptors with high affinity and specificity, inhibiting stress-mediated cell senescence, damage, inflammation, and tissue fibrosis.
These antibodies effectively reduce stress-mediated senescence, inflammation, and fibrosis, providing therapeutic benefits in conditions like psoriasis, heart failure, and acute kidney injury, while also protecting vascular and cardiac tissues from damage.